MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.
Growing
The company is in a growing phase, with the latest annual income totaling USD 33.03M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 33.03M.
Overvalued
The company’s latest PE is -3.31, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 79.92M shares, decreasing 19.15% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 3.29K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.80.